March 14, 2015 – The American Food and Drug Administration (FDA) just approved Crizotinib (Xalkori) to treat the patient subpopulation with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Crizotinib (Xalkori) is the first …

The use of Crizotinib (Xalkori) has been expanded to treat advanced NSCLC in the patient group who carries a ROS-1 gene alteration Read more »

Fukuizumi A, Miyanaga A, Seike M, Kato Y, Nakamichi S, Chubachi K, Matsumoto M, Noro R, Minegishi Y, Kunugi S, Kubota K, Gemma A BMC Res Notes 2015;8:165 PMID: 25899913 Abstract BACKGROUND: Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic …

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report Read more »

December 12, 2015 – The American Food and Drug Administration today approved Alectinib (Alecensa) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called …

Alectinib (Alecensa) approved for treatment of patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) Read more »

August 26, 2011 – Today, the  American Food and Drug Administration (FDA) has approved Crizotinib [Xalkori] to treat the patient subgroup with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) whos cancers express (i.e., test positive for the …

FDA Approves Crizotinib [Xalkori] with Companion Diagnostic Test for Non-Small Cell Lung Cancers (NSCLC) Positive for the Anaplastic Lymphoma Kinase (ALK) Gene Read more »